Claims
- 1. A compound having the structure:
- 2. A composition comprising (a) a compound as defined in claim 1.
- 3. A composition as defined in claim 2, further comprising:
(b) an adjuvant; (c) an anti-oxidant (d) a buffer; (e) a carrier; (f) a colorant; (g) a diluent; (h) a disintegrant; (i) an excipient; (j) a filler; (k) a flavorant; (l) a gelling agent; (m)a lubricant; (n) a neutralizing agent, (o) a preservative; or (p) any combination of any of the foregoing.
- 4. A composition as defined in claim 3, comprising an opiate receptor agonizing effective amount of said compound.
- 5. A composition as defined in claim 4, wherein said opiate receptor is a μ receptor.
- 6. A composition as defined in claim 3, comprising an analgesic effective amount of said compound.
- 7. A composition as defined in claim 3, comprising a sedative effective amount of said compound.
- 8. A composition as defined in claim 3, comprising an anti-tussive amount of said compound.
- 9. A composition as defined in claim 3, comprising an opioid withdrawal-relieving effective amount of said compound.
- 10. A composition as defined in claim 3, comprising an opioid addiction-relieving effective amount of said compound.
- 11. A composition as defined in claim 1, comprising 50% or more by weight of said compound.
- 12. A composition as defined in claim 1, comprising 90% or more by weight of said compound.
- 13. A composition as defined in claim 1, comprising 99.9% or more by weight of said compound.
- 14. A composition as defined in claim 3, comprising said compound in an amount sufficient to achieve a maximum blood concentration of from about 20 pg/ml to about 10 ng/ml of said compound.
- 15. A unit dosage form comprising a composition as defined in claim 2.
- 16. A unit dosage form as defined in claim 15, selected from the group consisting of tablets, pills, capsules, boluses, powders, granules, sterile parenteral solutions, sterile parenteral suspensions, elixirs, tinctures, metered aerosol, liquid sprays, drops, ampoules, autoinjector devices, suppositories, transdermal patches, and a lyophilized composition.
- 17. A unit dosage form as defined in claim 15, which is a sustained release unit dosage form.
- 18. A unit dosage form as defined in claim 15, comprising 50% or more by weight of said compound.
- 19. A unit dosage form as defined in claim 15, comprising 90% or more by weight of said compound.
- 20. A unit dosage form as defined in claim 15, comprising 99.9% or more by weight of said compound.
- 21. A method of stimulating μ opiate receptors in a patient in need thereof, said method comprising administering a μ opiate receptor agonizing effective amount of a composition as defined in claim 2 to said patient.
- 22. A method as defined in claim 21, wherein said administration is selected from the group consisting of oral, intravenous, intramuscular, subcutaneous, transdermal, pulmonary, ophthalmic, transmucosal, and buccal administration.
- 23. A method as defined in claim 21, wherein said method provides said compound in an amount sufficient to achieve a maximum blood concentration of about 10 ng/ml of said compound.
- 24. A method of preventing pain in a patient in need thereof, said method comprising administering an analgesic effective amount of a composition as defined in claim 2 to said patient.
- 25. A method as defined in claim 24, wherein said administration is selected from the group consisting of oral, intravenous, intramuscular, subcutaneous, transdermal, pulmonary, ophthalmic, transmucosal, epidural, intrathecal, and buccal administration.
- 26. A method as defined in claim 24, wherein said method provides said compound in an amount sufficient to achieve a maximum blood concentration of about 10 ng/ml to said patient
- 27. A method of treating pain in a patient in need thereof, said method comprising administering an analgesic effective amount of a composition as defined in claim 2 to said patient.
- 28. A method as defined in claim 27, wherein said administration is selected from the group consisting of oral, intravenous, intramuscular, subcutaneous, transdermal, pulmonary, ophthalmic, transmucosal, and buccal administration.
- 29. A method as defined in claim 27, wherein said method provides said compound in an amount sufficient to achieve a maximum blood concentration of about 10 ng/ml to said patient.
- 30. A method as defined in claim 27, wherein said pain is moderate or severe.
- 31. A method of sedating a patient in need thereof, said method comprising administering a sedating effective amount of a composition as defined in claim 2 to said patient.
- 32. A method as defined in claim 31, wherein said administration is selected from the group consisting of oral, intravenous, intramuscular, subcutaneous, transdermal, pulmonary, ophthalmic, transmucosal, epidural, intrathecal, and buccal administration.
- 33. A method as defined in claim 31, wherein said method provides said compound in an amount sufficient to achieve a maximum blood concentration of about 10 ng/ml to said patient.
- 34. A method of treating cough in a patient in need thereof comprising administering an anti-tussive effective amount of a composition as defined in claim 2 to said patient.
- 35. A method as defined in claim 34, wherein said method provides said compound in an amount sufficient to achieve a maximum blood concentration of from about 20 pg/ml to about 10 ng/ml to said patient.
- 36. A method of treating opioid withdrawal (abstinence syndrome) in a patient in need thereof comprising administering an opioid withdrawal-relieving effective amount of a composition as defined in claim 2 to said patient.
- 37. A method as defined in claim 36, wherein said method provides said compound in an amount sufficient to achieve a maximum blood concentration of about 10 ng/ml to said patient.
- 38. A method of treating opioid addiction in a patient in need thereof comprising administering an addiction-relieving effective amount of a composition as defined in claim 2 to said patient.
- 39. A method as defined in claim 38, wherein said method provides said compound in an amount sufficient to achieve a maximum blood concentration of about 10 ng/ml to said patient.
- 40. A kit comprising a composition as defined in claim 2, and a container, label, and instructions for use.
CROSS-REFERENCE TO RELATED APPLICATION
[0001] This application claims priority from U.S. Provisional Application Serial No. 60/272,819, filed Mar. 2, 2001, which is incorporated herein by reference in its entirety.
PCT Information
Filing Document |
Filing Date |
Country |
Kind |
PCT/US02/06766 |
3/4/2002 |
WO |
|